 |
 |
I found this abstract from the Fourth International Congress of Movement Disorders, Vienna, June 1996. It can be located in the journal "Movement Disorders", Vol. 11, Supplement 1, 1996 (paper 725, p. 194). What follows is my slight reduction of the abstract, without some of the stats. Clinical Improvement of Parkinsonian symptoms after parenteral application of NADH. W Kuhn et al, Department of Neurology, St Josef Hospital, Ruhr-University of Bochum Gudrunstr. 56, 44791 Bochum (?) Introduction: Reduced coenzyme nicotinamide adenine dinucleotide (NADH) may stimulate endogenous biosynthesis of L-Dopa (Vrecko, K et al. J Neural Transm Park Dis Dement Sect 1993; 5 (2): 147-156) and therefore may represent a new therapeutic approach to PD (Birkmayer, JG et al Acta Neurol Scand Suppl 1993; 146: 32-35). Material and Methods: To test the clinical potential of a newly developed pharmaceutical preparation (Mattern & Partner, Germany), NADH was intravenously applied over a period of 7 days (10mg/500ml 0.9% NaCl per day, infusion time 8am to 9am) in 14 patients...in advanced stages ...of PD. Mean duration of PD was 7.5 to 9.0 years. The clinical symptoms were scored by using the Unified PD Ratings Scale (UPDRS). The mean UPDRS score at day 0... was significantly higher [I guess this means worse] than after application of i.v.NADH over 7 days. Conclusion: Parenteral application of NADH may be of therapeutic value in PD and should further be investigated in double-blind, placebo-controlled trials.